Chief Business Officer
Gary Sutton has served as Ribon’s chief business officer since June 2022. Mr. Sutton brings over 18 years of experience in the BioPharma industry. Mr. Sutton most recently served as a Partner at Flagship Pioneering where he led the business development activities for the Pioneering Medicines group within Flagship. He is a lawyer by training and spent the majority of his career at Novartis, initially leading the Legal Transactions team and then heading up the Global BD&L Transactions and Negotiations team. While at Novartis he was responsible for the structuring, negotiation and execution of all business development transactions covering all disease areas for the global research division of Novartis, including mergers and acquisitions (IFM Tre, Admune), research and development collaborations (Aduro, Surface Oncology), co-development/co-promotion agreements (Xencor), program in-licenses (Xoma), equity investments (Caribou, Intellia, Arcus), and limited partner investments in venture funds (Atlas). He received the Novartis Oncology President’s award for his help executing the collaboration and license agreement with the University of Pennsylvania regarding novel cellular immunotherapies using chimeric antigen receptor T-cell (CART) technologies. More recently, he was instrumental in the leading the effort at Novartis to out-license shelved programs to interested parties including Pharma companies and investors that led to establishment of companies like RestorBio and Magenta, amongst others. He has previous experience at Kirkpatrick & Lockhart LLP (now K&L Gates LLP), Nixon Peabody LLP and UST Corp.
Mr. Sutton received his Juris Doctor from Northeastern University School of Law and his Bachelor of Science in Business Administration from Northeastern University.